Dibenzepin

• IUPAC: 10 - [2 - (dimethylamino) ethyl] -5-methyl -10, 11 - dihydro -5H- dibenzo [ b, e ] [1,4] diazepin- 11-one
• Latin: Dibenzepinum

N06AA08

Tricyclic antidepressants

Non-selective monoamine reuptake inhibitors

116-117 ° C

185 ° C ( 1.3 Pa )

8.25 ( monohydrochloride )

Soluble in ethanol, chloroform, water ( monohydrochloride )

194 mg · kg -1 ( LD50, mouse, oral)

Template: Infobox chemical / molecular formula search available

Dibenzepin ( Manufacturer: Novartis) is a tricyclic antidepressant that came on the German market in 1965. From the chemical structure it is related to the neuroleptics, benzodiazepines and some ( clozapine, olanzapine, quetiapine, zotepine ), but without sharing their pharmacological properties. Dibenzepin has a relatively short half-life of about 9 hours, at a plasma binding of 80%. It has a sedative effect, antidepressant and anxiolytic. It has the typical side effects of tricyclic antidepressants (qv).

Therapeutic doses of 240-720 mg per day can be used .. In contrast to other tricyclic antidepressants are toxic plasma levels of dibenzepin much higher (over 3000 ng / ml).

Use in pregnancy

There is evidence for risks of the human fetus, but the therapeutic benefit to the mother may outweigh. Dibenzepin should be used in pregnancy only if it is absolutely necessary.

Effect on the ability to drive and use machines

Dibenzepin may limit the responsiveness. This must be considered in relation to the ability to drive and use machines.

Trade names

Noveril TR (CH), Noveril retard (A)